Alimera Reports Favorable Safety And Efficacy Results From The 12-Month Interim Readout Of The Human PK Iluvien™ Study

Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the firs... [more]

View complete Press Release article